{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T23:23:47Z","timestamp":1791156227404,"version":"4.1.0"},"reference-count":40,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Kidney disease is a common complication of monoclonal immunoglobulin (MIg)\u2013secreting B-cell disorders and predominantly occurs in patients who do not meet the criteria for an overt hematological disease. To distinguish this situation from monoclonal gammopathy of undetermined significance, which lacks organ damage, the term monoclonal gammopathy of renal significance (MGRS) was introduced to depict the association of a small, otherwise indolent B-cell clone, with renal disease induced by the secreted MIg. The spectrum of renal disorders in MGRS is wide, encompassing both tubular and glomerular disorders, classified according to the composition of deposits and their ultrastructural pattern of organization. Renal lesions, independent of the tumor burden, are mostly governed by the molecular characteristics of the MIg variable domain and involve either direct (deposition or precipitation) or indirect (autoantibody activity, complement activation) mechanisms. The diagnosis, often suggested by careful analysis of renal and extrarenal symptoms, almost always requires histological confirmation by a kidney biopsy with light, immunofluorescence, and electron microscopy studies. Most patients do not have a known monoclonal gammopathy at presentation. Hematologic investigations should include serum and urine protein electrophoresis and immunofixation, serum-free light chain measurements, and bone marrow studies with flow cytometry and cytogenetics to determine the nature of the pathogenic clone (most commonly plasmocytic). Early diagnosis before the development of severe chronic kidney disease and rapid achievement of deep hematological response through clone-targeted chemotherapy (currently based on proteasome inhibitor and monoclonal anti-CD38 antibody\u2013based combinations for plasma cell clones) are the main factors influencing long-term renal and patient outcomes.<\/jats:p>","DOI":"10.1182\/hematology.2024000573","type":"journal-article","created":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T10:04:53Z","timestamp":1733479493000},"page":"489-498","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":9,"title":["Renal manifestations of MGUS"],"prefix":"10.1182","volume":"2024","author":[{"given":"Frank","family":"Bridoux","sequence":"first","affiliation":[{"name":"1 Department of Nephrology, Centre de r\u00e9f\u00e9rence maladies rares, Amylose AL et autres maladies par d\u00e9p\u00f4ts d'immunoglobulines monoclonales, Centre Hospitalier Universitaire Poitiers, Universit\u00e9 de Poitiers, Poitiers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samih H.","family":"Nasr","sequence":"additional","affiliation":[{"name":"2 Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Arnulf","sequence":"additional","affiliation":[{"name":"3 Department of Hematology and Immunology, Centre de r\u00e9f\u00e9rence maladies rares, Amylose AL et autres maladies par d\u00e9p\u00f4ts d'immunoglobulines monoclonales, H\u00f4pital Saint-Louis, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson","family":"Leung","sequence":"additional","affiliation":[{"name":"4 Department of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Sirac","sequence":"additional","affiliation":[{"name":"5 Joint Research Unit CNRS 7276, INSERM 1262, Centre de r\u00e9f\u00e9rence maladies rares, Amylose AL et autres maladies par d\u00e9p\u00f4ts d'immunoglobulines monoclonales, Centre Hospitalier Universitaire Limoges, Universit\u00e9 de Limoges, Limoges, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Jaccard","sequence":"additional","affiliation":[{"name":"6 Department of Hematology and Cellular Therapy, Centre de r\u00e9f\u00e9rence maladies rares, Amylose AL et autres maladies par d\u00e9p\u00f4ts d'immunoglobulines monoclonales, Centre Hospitalier Universitaire Limoges, Universit\u00e9 de Limoges, Limoges, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,12,6]]},"reference":[{"issue":"3","key":"2024121115511560900_hem2024000573C1","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.kint.2020.11.010","article-title":"Management of acute kidney injury in symptomatic multiple myeloma","volume":"99","author":"Bridoux","year":"2021","journal-title":"Kidney Int"},{"issue":"22","key":"2024121115511560900_hem2024000573C2","doi-asserted-by":"crossref","first-page":"4292","DOI":"10.1182\/blood-2012-07-445304","article-title":"Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant","volume":"120","author":"Leung","year":"2012","journal-title":"Blood"},{"issue":"20","key":"2024121115511560900_hem2024000573C3","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1056\/NEJMra1810907","article-title":"Monoclonal gammopathy of renal significance","volume":"384","author":"Leung","year":"2021","journal-title":"N Engl J Med"},{"issue":"14","key":"2024121115511560900_hem2024000573C4","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1182\/blood-2018-04-839480","article-title":"Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications","volume":"132","author":"Fermand","year":"2018","journal-title":"Blood"},{"issue":"10","key":"2024121115511560900_hem2024000573C5","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1681\/ASN.2020010054","article-title":"Rate and predictors of finding monoclonal gammopathy of renal significance (MGRS) lesions on kidney biopsy in patients with monoclonal gammopathy","volume":"31","author":"Klomjit","year":"2020","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"2024121115511560900_hem2024000573C6","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/nrneph.2018.8","article-title":"Animal models of monoclonal immunoglobulin-related renal diseases","volume":"14","author":"Sirac","year":"2018","journal-title":"Nat Rev Nephrol"},{"issue":"12","key":"2024121115511560900_hem2024000573C7","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1681\/ASN.2012060577","article-title":"Recurrent membranous nephropathy in an allograft caused by IgG3\u03ba targeting the PLA2 receptor","volume":"23","author":"Debiec","year":"2012","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"2024121115511560900_hem2024000573C8","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1053\/j.ajkd.2004.09.029","article-title":"Recurrent Goodpasture's disease secondary to a monoclonal IgA1-kappa antibody autoreactive with the alpha1\/alpha2 chains of type IV collagen","volume":"45","author":"Borza","year":"2005","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"2024121115511560900_hem2024000573C9","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1053\/j.ajkd.2021.12.014","article-title":"Complement activation and thrombotic microangiopathy associated with monoclonal gammopathy: a national French case series","volume":"80","author":"Martins","year":"2022","journal-title":"Am J Kidney Dis"},{"issue":"11","key":"2024121115511560900_hem2024000573C10","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1182\/blood-2016-08-737163","article-title":"Treatment of B-cell disorder improves renal outcome of patients with monoclonal gammopathy-associated C3 glomerulopathy","volume":"129","author":"Chauvet","year":"2017","journal-title":"Blood"},{"key":"2024121115511560900_hem2024000573C11","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.3389\/fimmu.2018.02260","article-title":"Both monoclonal and polyclonal immunoglobulin contingents mediate complement activation in monoclonal gammopathy associated-C3 glomerulopathy","volume":"9","author":"Chauvet","year":"2018","journal-title":"Front Immunol"},{"issue":"3","key":"2024121115511560900_hem2024000573C12","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1053\/j.ajkd.2024.01.530","article-title":"2024 update on classification, etiology, and typing of renal amyloidosis","volume":"84","author":"Leung","year":"2024","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"2024121115511560900_hem2024000573C13","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.kint.2020.06.039","article-title":"Results of a nation-wide cohort study suggest favorable long-term outcomes of clone- targeted chemotherapy in immunotactoid glomerulopathy","volume":"99","author":"Javaugue","year":"2021","journal-title":"Kidney Int"},{"issue":"2","key":"2024121115511560900_hem2024000573C14","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.kint.2020.07.037","article-title":"Immunotactoid glomerulopathy is a rare entity with monoclonal and polyclonal variants","volume":"99","author":"Nasr","year":"2021","journal-title":"Kidney Int"},{"issue":"2","key":"2024121115511560900_hem2024000573C15","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.kint.2022.03.030","article-title":"The characteristics of seronegative and seropositive non-hepatitis-associated cryoglobulinemic glomerulonephritis","volume":"102","author":"Javaugue","year":"2022","journal-title":"Kidney Int"},{"issue":"2","key":"2024121115511560900_hem2024000573C16","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.kint.2024.02.027","article-title":"Monoclonal immunoglobulin crystalline nephropathies","volume":"106","author":"Nasr","year":"2024","journal-title":"Kidney Int"},{"issue":"3","key":"2024121115511560900_hem2024000573C17","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.kint.2022.11.026","article-title":"Pathological characteristics of light chain crystalline podocytopathy","volume":"103","author":"Nasr","year":"2023","journal-title":"Kidney Int"},{"issue":"5","key":"2024121115511560900_hem2024000573C18","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1681\/ASN.2015020185","article-title":"Light chain proximal tubulopathy: clinical and pathologic characteristics in the modern treatment era","volume":"27","author":"Stokes","year":"2016","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"2024121115511560900_hem2024000573C19","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/leu.2016.195","article-title":"Current anti-myeloma therapies in renal manifestations of monoclonal light chain-associated Fanconi syndrome: a retrospective series of 49 patients","volume":"31","author":"Vignon","year":"2017","journal-title":"Leukemia"},{"issue":"9","key":"2024121115511560900_hem2024000573C20","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1093\/ndt\/gfq129","article-title":"Crystal-storing histiocytosis with renal Fanconi syndrome: pathological and molecular characteristics compared with classical myeloma-associated Fanconi syndrome","volume":"25","author":"El Hamel","year":"2010","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"2024121115511560900_hem2024000573C21","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1182\/blood-2018-09-872028","article-title":"Randall-type monoclonal immunoglobulin deposition disease: novel insights from a nationwide cohort study","volume":"133","author":"Joly","year":"2019","journal-title":"Blood"},{"issue":"26","key":"2024121115511560900_hem2024000573C22","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1182\/blood-2015-07-658872","article-title":"Natural history and outcome of light chain deposition disease","volume":"126","author":"Sayed","year":"2015","journal-title":"Blood"},{"issue":"11","key":"2024121115511560900_hem2024000573C23","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1002\/ajh.24528","article-title":"Outcomes of patients with renal monoclonal immunoglobulin deposition disease","volume":"91","author":"Kourelis","year":"2016","journal-title":"Am J Hematol"},{"issue":"9","key":"2024121115511560900_hem2024000573C24","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1681\/ASN.2009010110","article-title":"Proliferative glomerulonephritis with monoclonal IgG deposits","volume":"20","author":"Nasr","year":"2009","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"2024121115511560900_hem2024000573C25","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.mayocp.2015.01.024","article-title":"Hematologic characteristics of proliferative glomerulonephritides with nonorganized monoclonal immunoglobulin deposits","volume":"90","author":"Bhutani","year":"2015","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"2024121115511560900_hem2024000573C26","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1093\/ndt\/gfz176","article-title":"Proliferative glomerulonephritis with monoclonal immunoglobulin deposits: a nephrologist perspective","volume":"36","author":"Bridoux","year":"2021","journal-title":"Nephrol Dial Transplant"},{"issue":"11","key":"2024121115511560900_hem2024000573C27","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.2215\/CJN.00650110","article-title":"The incidence of major hemorrhagic complications after renal biopsies in patients with monoclonal gammopathies","volume":"5","author":"Fish","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"2024121115511560900_hem2024000573C28","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.kint.2020.02.025","article-title":"DNAJB9-positive monotypic fibrillary glomerulonephritis is not associated with monoclonal gammopathy in the vast majority of patients","volume":"98","author":"Said","year":"2020","journal-title":"Kidney Int"},{"issue":"1","key":"2024121115511560900_hem2024000573C29","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.kint.2021.02.038","article-title":"Immunofluorescence staining for immunoglobulin heavy chain\/light chain on kidney biopsies is a valuable ancillary technique for the diagnosis of monoclonal gammopathy-associated kidney diseases","volume":"100","author":"Nasr","year":"2021","journal-title":"Kidney Int"},{"issue":"9","key":"2024121115511560900_hem2024000573C30","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1016\/j.mayocp.2020.06.029","article-title":"Amyloid typing by mass spectrometry in clinical practice: a comprehensive review of 16,175 samples","volume":"95","author":"Dasari","year":"2020","journal-title":"Mayo Clin Proc"},{"issue":"22","key":"2024121115511560900_hem2024000573C31","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1182\/blood-2013-05-495929","article-title":"How I treat monoclonal gammopathy of renal significance (MGRS)","volume":"122","author":"Fermand","year":"2013","journal-title":"Blood"},{"issue":"5","key":"2024121115511560900_hem2024000573C32","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1038\/s41375-019-0667-6","article-title":"IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features","volume":"34","author":"Sidana","year":"2020","journal-title":"Leukemia"},{"issue":"2","key":"2024121115511560900_hem2024000573C33","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.kint.2021.10.017","article-title":"RNA-based immunoglobulin repertoire sequencing is a new tool for the management of monoclonal gammopathy of renal (kidney) significance","volume":"101","author":"Javaugue","year":"2022","journal-title":"Kidney Int"},{"issue":"1","key":"2024121115511560900_hem2024000573C34","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-based treatment for immunoglobulin light-chain amyloidosis","volume":"385","author":"Kastritis","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"2024121115511560900_hem2024000573C35","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/bjh.17052","article-title":"Daratumumab-based therapy for patients with monoclonal gammopathy of renal significance","volume":"193","author":"Kastritis","year":"2021","journal-title":"Br J Haematol"},{"issue":"8","key":"2024121115511560900_hem2024000573C36","doi-asserted-by":"crossref","first-page":"e488","DOI":"10.1016\/j.clml.2020.03.013","article-title":"Venetoclax in a patient with light chain deposition disease secondary to MGRS that progressed after kidney transplantation","volume":"20","author":"Leung","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"8","key":"2024121115511560900_hem2024000573C37","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41408-022-00714-5","article-title":"Outcomes of renal transplantation in patients with AL amyloidosis: an international collaboration through the International Kidney and Monoclonal Gammopathy Research Group","volume":"12","author":"Havasi","year":"2022","journal-title":"Blood Cancer J"},{"issue":"2","key":"2024121115511560900_hem2024000573C38","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1053\/j.ajkd.2021.04.015","article-title":"Kidney transplantation in patients with monoclonal gammopathy of renal significance (MGRS)-associated lesions: a case series","volume":"79","author":"Heybeli","year":"2022","journal-title":"Am J Kidney Dis"},{"issue":"36","key":"2024121115511560900_hem2024000573C39","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","article-title":"New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes","volume":"30","author":"Palladini","year":"2012","journal-title":"J Clin Oncol"},{"issue":"15","key":"2024121115511560900_hem2024000573C40","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1182\/blood-2014-04-570010","article-title":"A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis","volume":"124","author":"Palladini","year":"2014","journal-title":"Blood"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2024\/1\/489\/2346793\/489bridoux.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2024\/1\/489\/2346793\/489bridoux.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T15:26:47Z","timestamp":1733930807000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2024\/1\/489\/526240\/Renal-manifestations-of-MGUS"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,6]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12,6]]},"published-print":{"date-parts":[[2024,12,6]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2024000573","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12,6]]},"published":{"date-parts":[[2024,12,6]]}}}